1. Home
  2. PKOH vs STTK Comparison

PKOH vs STTK Comparison

Compare PKOH & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park-Ohio Holdings Corp.

PKOH

Park-Ohio Holdings Corp.

HOLD

Current Price

$24.40

Market Cap

299.5M

Sector

Industrials

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$5.93

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKOH
STTK
Founded
1907
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
299.5M
275.9M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
PKOH
STTK
Price
$24.40
$5.93
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$37.00
$7.00
AVG Volume (30 Days)
23.2K
574.2K
Earning Date
06-11-2026
01-01-0001
Dividend Yield
2.03%
N/A
EPS Growth
N/A
53.02
EPS
1.70
N/A
Revenue
$1,599,100,000.00
$1,000,000.00
Revenue This Year
$6.31
N/A
Revenue Next Year
$4.18
N/A
P/E Ratio
$14.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.52
$0.69
52 Week High
$29.50
$6.13

Technical Indicators

Market Signals
Indicator
PKOH
STTK
Relative Strength Index (RSI) 40.92 71.75
Support Level $19.21 $1.85
Resistance Level $29.00 N/A
Average True Range (ATR) 1.37 0.40
MACD -0.40 0.17
Stochastic Oscillator 5.70 87.70

Price Performance

Historical Comparison
PKOH
STTK

About PKOH Park-Ohio Holdings Corp.

Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: